(Q36916934)

17 August 2017

1 reference

title

Simvastatin: present and future perspectives (English)

1 reference

17 August 2017

1 reference

Jennifer G Robinson

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

13

1 reference

17 August 2017

page(s)

2159-2127

1 reference

Preventing chronic diseases: how many lives can we save?

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Impact of Baby Boomers on hospitalizations for coronary heart disease and stroke in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Taking simvastatin in the morning compared with in the evening: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Myocardial infarction: ACE inhibitors for all? For ever?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Safety considerations with niacin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Simvastatin, fenofibrate, and rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Rhabdomyolysis in association with simvastatin and amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Statin-associated rhabdomyolysis triggered by grapefruit consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Statin safety and drug interactions: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Safety of statins: focus on clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Safety of aggressive lipid management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

An assessment of statin safety by neurologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

An assessment of statin safety by nephrologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Statin safety: lessons from new drug applications for marketed statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Statins and cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Reconsidering medication appropriateness for patients late in life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Is it time for a cardiovascular primary prevention trial in the elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Rhabdomyolysis due to interaction of simvastatin with mibefradil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2159

10.1517/14656566.8.13.2159

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference